MOR Stock Overview
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MorphoSys AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.81 |
| 52 Week High | €24.92 |
| 52 Week Low | €11.81 |
| Beta | 0.76 |
| 1 Month Change | 24.92% |
| 3 Month Change | 38.63% |
| 1 Year Change | 13.49% |
| 3 Year Change | -79.59% |
| 5 Year Change | -73.99% |
| Change since IPO | 252.74% |
Recent News & Updates
Recent updates
Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?
May 16
MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%
Apr 17MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be
Nov 26News Flash: 10 Analysts Think MorphoSys AG (ETR:MOR) Earnings Are Under Threat
Mar 21MorphoSys AG (ETR:MOR) Analysts Just Slashed Next Year's Revenue Estimates By 10%
Jan 12Health Check: How Prudently Does MorphoSys (ETR:MOR) Use Debt?
Dec 04Is MorphoSys (ETR:MOR) A Risky Investment?
Aug 19These Analysts Just Made A Huge Downgrade To Their MorphoSys AG (ETR:MOR) EPS Forecasts
Mar 17Will Weakness in MorphoSys AG's (ETR:MOR) Stock Prove Temporary Given Strong Fundamentals?
Feb 22What Kind Of Shareholders Hold The Majority In MorphoSys AG's (ETR:MOR) Shares?
Jan 17The MorphoSys (ETR:MOR) Share Price Has Gained 62% And Shareholders Are Hoping For More
Dec 14Shareholder Returns
| MOR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.5% | -0.04% | -1.3% |
| 1Y | 13.5% | -4.7% | -8.5% |
Return vs Industry: MOR exceeded the German Biotechs industry which returned -6.1% over the past year.
Return vs Market: MOR exceeded the German Market which returned -8.1% over the past year.
Price Volatility
| MOR volatility | |
|---|---|
| MOR Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: MOR is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MOR's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 623 | Jean-Paul Kress | https://www.morphosys.com |
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1.
MorphoSys AG Fundamentals Summary
| MOR fundamental statistics | |
|---|---|
| Market Cap | €816.91m |
| Earnings (TTM) | -€72.84m |
| Revenue (TTM) | €299.12m |
2.7x
P/S Ratio-11.2x
P/E RatioIs MOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOR income statement (TTM) | |
|---|---|
| Revenue | €299.12m |
| Cost of Revenue | €61.71m |
| Gross Profit | €237.41m |
| Other Expenses | €310.25m |
| Earnings | -€72.84m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 09, 2023
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 79.37% |
| Net Profit Margin | -24.35% |
| Debt/Equity Ratio | 246.7% |
How did MOR perform over the long term?
See historical performance and comparison